XML 131 R103.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Contingencies (Details) R$ in Millions, $ in Millions |  |  | 1 Months Ended | 154 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 31, 2022 lawsuit | Sep. 30, 2021 BRL (R$) | Sep. 30, 2021 USD ($) | Jul. 31, 2021 claim | Jun. 30, 2021 BRL (R$) patent | Dec. 31, 2019 | Jul. 31, 2019 BRL (R$) | Jul. 31, 2018 BRL (R$) | Dec. 31, 2021 site plaintiff lawsuit claimant | Sep. 30, 2018 patent | Nov. 30, 2017 lawsuit | Jan. 31, 2013 lawsuit | Jul. 31, 2012 lawsuit | Dec. 31, 2011 lawsuit
Unfavorable Regulatory Action |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of sites jointly and severally liable for cleanup (fewer than) | site |  |  |  |  |  |  |  |  | 10 |  |  |  |  |
Actos | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  | 4 |  |  |  |  |
Byetta | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  | 570 |  |  |  |  |
Number of plaintiffs | plaintiff |  |  |  |  |  |  |  |  | 805 |  |  |  |  |
Number of claimants | claimant |  |  |  |  |  |  |  |  | 20 |  |  |  |  |
Byetta | Product Liability | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of cases denied | 311 |  |  |  |  |  |  |  |  |  |  |  |  |
Byetta | Pancreatic Cancer or Thyroid Cancer | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  | 565 |  |  |  |  |
Number of plaintiffs | plaintiff |  |  |  |  |  |  |  |  | 800 |  |  |  |  |
Byetta | Pancreatitis | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of plaintiffs | plaintiff |  |  |  |  |  |  |  |  | 6 |  |  |  |  |
Byetta | Ampullary Cancer | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of plaintiffs | plaintiff |  |  |  |  |  |  |  |  | 1 |  |  |  |  |
Byetta | Los Angeles | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  | 55 |  |  |  |  |
Number of plaintiffs | plaintiff |  |  |  |  |  |  |  |  | 285 |  |  |  |  |
Byetta | Southern District of California | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  | 515 |  |  |  |  |
Number of plaintiffs | plaintiff |  |  |  |  |  |  |  |  | 515 |  |  |  |  |
Byetta | Various State Domiciles | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  | 2 |  |  |  |  |
Number of plaintiffs | plaintiff |  |  |  |  |  |  |  |  | 2 |  |  |  |  |
Byetta | Various State Domiciles | Product Liability | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of cases denied | 17 |  |  |  |  |  |  |  |  |  |  |  |  |
Cialis® | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  | 350 |  |  |  |  |
Jardiance® | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  | 5 |  |  |  |  |
Humalog, Humulin and Forteo |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  | 2 |  |  |  |  |
Insulin |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of claims dismissed | claim |  |  |  | 3 |  |  |  |  |  |  |  |  |  |
Alimta Patent Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Limited initial market entry, supply term |  |  |  |  |  | 21 days |  |  |  |  |  |  |  |
Emgality Patent Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents | patent |  |  |  |  | 2 |  |  |  |  | 9 |  |  |  |
Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. | Actos | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  |  |  |  |  |  | 1
Weiler v. Takeda Canada Inc. et al. | Actos | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  |  |  |  |  | 1 |
Weiler v. Takeda Canada Inc. et al. | Actos | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  |  |  | 1 |  |  |
Epp v. Takeda Canada Inc. et al. | Actos | Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  |  |  |  | 1 |  |
Brazil | Employee Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pending lawsuits |  |  |  |  |  |  |  |  | 25 |  |  |  |  |
Damages awarded, value |  | R$ 950 | $ 170 |  | R$ 100 |  | R$ 500 | R$ 300 |  |  |  |  |  |

X
- Definition Litigation, Claims Dismissed, Number + References No definition available. + Details
Name: | lly_LitigationClaimsDismissedNumber
Namespace Prefix: | lly_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term + References No definition available. + Details
Name: | lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm
Namespace Prefix: | lly_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Number Of Claimants + References No definition available. + Details
Name: | lly_LossContingencyNumberOfClaimants
Namespace Prefix: | lly_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number Of Patents + References No definition available. + Details
Name: | lly_LossContingencyNumberOfPatents
Namespace Prefix: | lly_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup + References No definition available. + Details
Name: | lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup
Namespace Prefix: | lly_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of claims dismissed. + References No definition available. + Details
Name: | us-gaap_LossContingencyClaimsDismissedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of damages awarded to the plaintiff in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of plaintiffs that have filed claims pertaining to a loss contingency. + References No definition available. + Details
Name: | us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of pending claims pertaining to a loss contingency. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 + Details
Name: | us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_ActosMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_ByettaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | lly_PlaintiffAllegationsAxis=lly_PancreaticCancerOrThyroidCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | lly_PlaintiffAllegationsAxis=lly_PancreatitisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | lly_PlaintiffAllegationsAxis=lly_AmpullaryCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | lly_DomicileOfLitigationAxis=lly_LosAngelesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | lly_DomicileOfLitigationAxis=lly_SouthernDistrictOfCaliforniaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | lly_DomicileOfLitigationAxis=lly_VariousStateDomicilesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_CialisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_JardianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_InsulinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=lly_AlimtaPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=lly_EmployeeLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |